17 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 21 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 17, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Cholera: new trials by email Literature Review of Cholera trials Research Report on Cholera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ondansetron to Prevent Oral Rehydration Failure in Children With Cholera Ondansetron, Standard Cholera Care - Cholera (Disorder) | Phase 2 | Not yet recruiting | Public Interest Science Center | 120 | 2026-10-20 | 2026-10-19 |
| Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera VR-AD-1005, Placebo - Cholera | Phase 2 | Completed | Hunazine Biotech S.L. | 150 | 2024-02-11 | 2026-06-02 |
| Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea Next Generation ORS (oral rehydration solution) (including placebo, Current standard control ORS (oral rehydration solution) - Diarrhea, Cholera | Phase 2 / Phase 3 | Completed | University of Florida | 396 | 2023-08-21 | 2026-04-14 |
| Single Dose Azithromycin to Prevent Cholera in Children Azithromycin, Placebo - Cholera | Phase 2 | Completed | Massachusetts General Hospital | 2475 | 2021-10-31 | 2026-08-07 |
| Cholera Anti-Secretory Treatment Trial iOWH032, Placebo, V. cholerae Challenge - Cholera | Phase 2 | Completed | PATH | 47 | 2019-11-04 | 2021-03-25 |
| Extended Dose Intervals With Oral Cholera Vaccine in Cameroon killed whole cell oral cholera vaccine - Adverse Reaction to Cholera Vaccine, Cholera Vaccination Reaction | Phase 2 | Completed | Johns Hopkins Bloomberg School of Public Health | 181 | 2018-10-23 | 2022-10-05 |
| Immunologic Responses to a Live Attenuated Oral Cholera Vaccine Vaxchora - Cholera | Phase 2 | Completed | Emory University | 34 | 2017-08-29 | 2026-02-13 |
| Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine HL-OCV, Shanchol - Cholera | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 840 | 2016-07-01 | 2018-11-02 |
| Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine Cholvax, Shanchol - Cholera | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 2052 | 2016-04-01 | 2017-06-16 |
| Safety and Immunogenicity of a Killed Oral Cholera Vaccine in Infants Bivalent killed oral cholera vaccine, Killed Escherichia coli K12 placebo - Cholera, Diarrhea | Phase 2 | Unknown | International Vaccine Institute | 300 | 2015-12-01 | 2015-05-04 |
| PXVX0200 (CVD103-HgR) vs Shanchol in Mali PXVX0200 10E8, PXVX0200 10E9, Placebo - Cholera | Phase 2 | Completed | University of Maryland, Baltimore | 150 | 2014-07-01 | 2019-09-26 |
| Efficacy of iOWH032 in Dehydrating Cholera iOWH032 - Secretory Diarrhea | Phase 2 | Withdrawn | PATH | 2014-06-01 | 2014-09-26 | |
| Slow Versus Rapid Rehydration of Severely Malnourished Children Rapid dehydration, Slow rehydration - Diarrhea | Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 208 | 2011-05-01 | 2014-08-21 |
| Study of Alternative Vaccination Schedule of Oral Cholera Vaccine Modified killed oral cholera vaccine at 14 day interval, Modified killed oral cholera vaccine at 28 day interval - Cholera, Diarrhoea | Phase 2 | Completed | International Vaccine Institute | 386 | 2010-12-01 | 2013-09-25 |
| Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults CholeraGarde®, Placebo - Cholera, Vibrio Infections | Phase 2 | Completed | International Vaccine Institute | 32 | 2010-07-01 | 2012-03-30 |
| Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants Peru-15 Vaccine, Placebo - Cholera, Diarrhea | Phase 2 | Terminated | International Vaccine Institute | 74 | 2008-11-01 | 2012-08-01 |
| Studies of Immune Responses to Orally Administered Vaccines in Developing Country Placebo, Control, Zinc Sulphate - Cholera, Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 1016 | 2008-02-01 | 2011-07-12 |
| Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine Killed bivalent whole cell oral cholera vaccine, Heat Killed E. coli Placebo - Cholera, Diarrhea | Phase 2 | Completed | International Vaccine Institute | 160 | 2007-06-01 | 2009-12-07 |
| Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata killed whole cell oral cholera vaccine, Heat Killed E. coli - Cholera | Phase 2 | Completed | International Vaccine Institute | 200 | 2005-08-01 | 2008-07-04 |
| Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine killed oral cholera vaccine - Cholera | Phase 2 | Completed | International Vaccine Institute | 150 | 2005-05-01 | 2006-11-10 |
Showing 20 of 21. Sign in to see all of them.
Diarrhea (8) · Vibrio Infections (5) · Dehydration (2) · Osteoarthritis (2) · Communicable Diseases (1) · Malnutrition (1) · Typhoid Fever (1) · Vomiting (1)
Bacterial Infections (21) · Bacterial Infections and Mycoses (21) · Gram-Negative Bacterial Infections (21) · Infections (21) · Vibrio Infections (16) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (9) · Signs and Symptoms, Digestive (9) · Pathologic Processes (3) · Arthritis (2) · Joint Diseases (2) · Metabolic Diseases (2) · Musculoskeletal Diseases (2) · Nutritional and Metabolic Diseases (2) · Rheumatic Diseases (2)
shanchol (5) · IOWH-032 (2) · Peru 15 (2) · Albendazole (1) · Anti-Bacterial Agents (1) · Arsenic (1) · Azithromycin (1) · Calcium (1) · ORALIT (1) · Ondansetron (1) · Vaxchora (1) · World Health Organization oral rehydration solution (1) · Zinc Sulfate (1) · secnidazole (1)
International Vaccine Institute (7) · International Centre for Diarrhoeal Disease Research, Bangladesh (5) · PATH (2) · Emory University (1) · Hunazine Biotech S.L. (1) · Johns Hopkins Bloomberg School of Public Health (1) · Massachusetts General Hospital (1) · Public Interest Science Center (1) · University of Florida (1) · University of Maryland, Baltimore (1)
Bangladesh (10) · India (5) · United States (2) · Cameroon (1) · Mali (1) · Republic of the Congo (1) · Thailand (1) · Vietnam (1)
Firdausi Qadri, Dr. (2) · Alok K Deb, PhD, MDDS (1) · Armel Landry Batchi-Bouyou, MD, PhD, MPH (1) · Dang Duc Anh, PhD (1) · David Sack, MD (1) · Dipika Sur, MD, DPH (1) · Firdausi Qadri, PhD (1) · Jason B Harris, MD, MPH (1) · Jason B, MD, MPH (1) · John Clemens, MD (1) · Milagritos D Tapia, MD (1) · Nadine Rouphael, MD (1) · Sam Cheng, MD. PhD (1) · Samba O Sow, MD, MS (1)
PMID 22461716, PMID 16760521, PMID 17055622, PMID 18398491, PMID 18769066, PMID 19761838, PMID 21907255, PMID 24101640, PMID 29021299, PMID 34218960, PMID 34478460, PMID 34793441
R01AI137127 (1), R01HD102540 (1), R21AI169282 (1)